ANRO
Alto Neuroscience, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 56 | +2 | 11.54M | $304.54M | +10 | −8 |
| Q1 2026 | 55 | +7 | 8.39M | $188.63M | +8 | −1 |
| Q4 2025 | 48 | +2 | 8.42M | $149.83M | +3 | −1 |
| Q3 2025 | 15 | +1 | 4.77M | $19.16M | +1 | n/a |
| Q2 2025 | 12 | 0 | 4.77M | $10.50M | +1 | −1 |
| Q1 2025 | 9 | +1 | 3.54M | $7.65M | +2 | −1 |
| Q4 2024 | 8 | +2 | 5.27M | $22.30M | +2 | n/a |
| Q3 2024 | 5 | 0 | 2.33M | $26.66M | +2 | −2 |
| Q2 2024 | 5 | n/a | 1.98M | $21.15M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 1.05M | n/a | $11.22M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 645.83K | n/a | $6.90M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 188.97K | n/a | $2.02M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Norges Bank ✦ (passive) | 76.67K | n/a | $819,624 | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Millennium Management ✦ | 16.84K | n/a | $179,998 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 108 holders, 26.83M shares, $592.78M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 23.17K sh · $597,290
Officer · 886 sh · $23,807
Officer · 110.83K sh · $2.95M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology